EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience

Benjamin Heyman iD, Michael Choi, Thomas J Kipps

eJHaem · 2026-06 · 7 (3)

DOI: 10.1002/jha2.70280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eJHaem, online erschienen am 18.06.2026. Verfasst von Benjamin Heyman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Regenerative Medicine Department of Medicine UC San Diego Moores Cancer Center UC San Diego La Jolla California USA. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The optimal venetoclax‐based treatment for patients with relapsed/refractory (R/R) CLL is still unknown, especially for high‐risk patients.

Methods

We performed a retrospective analysis of 98 patients with R/R CLL treated with venetoclax‐based regimens. Patients received venetoclax alone or in combination with rituximab (VenR), obinutuzumab (VenO), or a BTKi (primarily ibrutinib).

Results

Combination groups achieved higher complete remission (CR) and uMRD rates: VenO (CR 68%, uMRD 86%), VenR (CR 63%, uMRD 82%), Ven + BTKi (CR 43%, uMRD 70%), versus monotherapy (CR 51%, uMRD 67%). At a median 52‐month follow‐up, median PFS was superior in combination arms (76.6 months) compared to monotherapy (58.9 months, p = 0.04).

Conclusion

This analysis validates, in a real‐world academic cohort, that venetoclax‐based combination therapy, particularly with obinutuzumab or BTKi, yields higher rates of deep remission and superior PFS compared to monotherapy for R/R CLL.

Schlagwörter

Stichwörter der Autor:innen

BTKichronic lymphocytic leukemiaminimal residual diseaseobinutuzumabrelapsed/refractoryrituximabvenetoclax

Autor:innen und Institutionen

  • Division of Regenerative Medicine Department of Medicine UC San Diego Moores Cancer Center UC San Diego La Jolla California USA.
  • Division of Hematology/Oncology Department of Medicine UC San Diego La Jolla California USA.
  • Center for Novel Therapeutics Division of Hematology/Oncology Department of Medicine UC San Diego La Jolla California USA.

ORCID-Profile: Benjamin Heyman

Zitieren

APA

Heyman, B., Choi, M., & Kipps, T. J. (2026). Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience. eJHaem, 7(3). https://doi.org/10.1002/jha2.70280

Vancouver

Heyman B, Choi M, Kipps TJ. Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience. eJHaem. 2026;7(3). doi:10.1002/jha2.70280

BibTeX
@article{Heyman2026,
  author = {Heyman, Benjamin and Choi, Michael and Kipps, Thomas J},
  title = {Comparison of Venetoclax‐Based Treatments for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Single‐Center Real‐World Experience},
  journal = {eJHaem},
  year = {2026},
  volume = {7},
  number = {3},
  doi = {10.1002/jha2.70280}
}
Kostenlos starten →